NCT02437526Enrolling by invitation
Analytic Treatment Interruption (ATI) to Assess HIV Cure
Analytic Treatment Interruption of Antiretroviral Therapy to Assess for HIV Cure
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
This study is designed to determine if individual patients with HIV infection have been cured of the infection. To do this, antiretroviral therapy is discontinued under close medical supervision and the patient monitored over time for reactivation of infection.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 5 May 2015
- Start date
- 1 May 2015
- Primary completion date
- 31 May 2035
- Lead sponsor
- Mayo Clinic
- Diseases
- HIV
- NCT number
- NCT02437526
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 1 May 2015 to the primary completion date, 31 May 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or current infections that are at high risk of reactivating with immune suppression, in whom there are no effective antimicrobial prophylaxis options
- Evidence of active viral replication in patients co-infected with Hepatitis B virus (HBV). Treatment should be provided to suppress HBV replication with agents that do not have activity against HIV (ie entecavir) prior to consideration for ATI.
Other illness
- Advanced cardiopulmonary or liver disease
- History of untreated solid or hematologic malignancies
- Evidence of viral replication with Hepatitis C virus (HCV), together with evidence of any hepatic fibrosis or inflammation. Such patients should be offered HCV treatment first.
Other
- Women who are pregnant or nursing
- Women who can become pregnant who are unable or unwilling to use both barrier and pharmacologic contraceptives during the ATI
Who the study is looking for
- Age ≥ 18 years
- HIV-1 infected with the potential to have been cured of infection in the course of routine clinical care in the opinion of the treating physician and study team
- Have an undetectable plasma HIV-1 RNA and undetectable proviral DNA on suppressive antiretroviral therapy on at least two consecutive measures for at least 6 months
- Able and willing to either abstain from sexual activity or use barrier contraceptives during the ATI
- Negative serum β-HCG pregnancy test in women with childbearing potential
- Have the ability to give appropriate informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.